Epizyme (EPZM) Tops Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Epizyme Reports First Quarter 2017 Results and Provides Corporate Update
May 8, 2017 7:00 AM EDTInterim Phase 2 Data of Tazemetostat in Molecularly Defined Solid Tumors and NHL to be Presented at Scientific Meetings in June
Conference Call on Interim Solid Tumor Data to be Held on May 18, 2017
Conference Call on Interim NHL Data to be Held on June 14, 2017
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today reported operating results for the first quarter 2017 and reiterated timelines for its upcoming data presentations.
Upcoming... More



